Asset profile
Anastrozole
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Anastrozole: this drug | Approved | Small molecule | Aromatase | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Letrozole | Approved | Small molecule | Aromatase | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | ||
| Gemcitabine | Approved | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(39 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
November 2026 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04906395 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05307705 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-22 · NCT04886531 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT04553770 · CT.gov ↗
What to watch
Early phase / not applicableCerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences, Exercise, VascularNot yet recruiting
Est. primary completion 2026-12-31 · NCT07212712 · CT.gov ↗
What to watch
2027 (8)
January 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
April 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT05501704 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT01953588 · CT.gov ↗
What to watch
Phase 3Klinefelter SyndromeRecruiting
Est. primary completion 2027-04-30 · NCT05586802 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT04469764 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03304080 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-11-30 · NCT05837455 · CT.gov ↗
What to watch
2028 (9)
May 2028 (2)
Early phase / not applicableSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite AthletesEnrolling by invitation
Est. primary completion 2028-05-01 · NCT07568574 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
June 2028 (2)
July 2028 (1)
Phase 1Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia …Recruiting
Est. primary completion 2028-07 · NCT07604272 · CT.gov ↗
What to watch
August 2028 (2)
November 2028 (1)
Phase 2Ductal Carcinoma in SituRecruiting
Est. primary completion 2028-11 · NCT06075953 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05524584 · CT.gov ↗
What to watch
2029 (6)
May 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05 · NCT07174336 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-06-30 · NCT06507618 · CT.gov ↗
What to watch
July 2029 (2)
August 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
2030 (7)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-10 · NCT04584853 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07581834 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.